Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

Here are 4 economic indicators that impact stocks and investors must pay attention to

There are several economic indicators that impact stocks, both on the ASX and internationally. Whenever data is released, it can swing market indices in a particular direction, sometimes the opposite direction to where it had been heading earlier in the day. This is not only if the data changes from one period to another, but…

ByNick SundichAugust 19, 2024

As lower interest rates loom, here are 6 ASX stocks that will benefit from forthcoming rate cuts

Here 6 ASX stocks that will benefit from lower interest rates! AGL Energy (ASX:AGL) You might think AGL is on this list because people will have an easier time paying their electricity bills. Not quite for two reasons: First, Blind Freddy could tell you that, and Second, people are still paying their bills. We were…

ByNick SundichAugust 14, 2024

Here’s why investors fear a US recession, and whether the fears are justified

Investors fear a US recession - there's no denying it and there's no other explanation for the market correction in the last week. But are these fears justified? Why investors fear a US recession Because there are data points that are showing markets could be headed that way. There was a very fine tightrope central banks…

ByNick SundichAugust 6, 2024

Is CSL (ASX:CSL) now facing a more difficult FY24 than investors first thought?

After a decade of nothing but good news for investors in CSL (ASX:CSL), shares fell by ~25% between June and October, a decline sparked by profit downgrade and consequential fears that the company's run as the poster child for the ASX biotech sector coming to an end? First published June 21, 2023; last updated December 4,…

ByNick SundichJune 21, 2023

Why did biotech shares underperform in 2022 and will they rebound with a vengence in 2023?

In the past year, biotech shares have performed poorly. Why has this been the case and will things be better in 2023? SIGN UP FOR THE STOCKS DOWN UNDER NEWSLETTER NOW! 1. Investor distaste for high risk assets For one, investors have been put off by the high risk associated with investing in biotech shares as…

ByNick SundichFebruary 24, 2023

Which ASX health stocks might get FDA approval in 2023?

It is the dream of many ASX health stocks and their investors for their company's device or drug to be approved by the FDA, the USA's medical regulator. This is because it unlocks the world's largest healthcare market.Companies that achieved that feat recently included hearing aid company Nuheara (ASX:NUH), along with infant formula stocks A2…

ByNick SundichDecember 22, 2022

Immutep (ASX: IMM) has massive potential!

Immutep ( ASX: IMM ) develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. It has several product candidates at different phases of clinical trials. But its lead product candidate is Eftilagimod Alpha (Efti), a recombinant protein that is in phase 2b clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. …

ByMarc KennisNovember 30, 2022

Actinogen Medical (ASX: ACW): Good news on phase 2 trials can catapult this stock

Working on a new drug for Alzheimer’s disease Actinogen Medical (ASX: ACW) is a Sydney-based biotechnology company working on finding treatments for Alzheimer’s and other neurological diseases. It’s working on a number of drugs, but its Xanamem’s recent clinical developments are what’s got the market excited. No time to do stock research,…

ByMarc KennisSeptember 29, 2022

Pfizer delivers the goods on a COVID-19 vaccine

10 November 2020One of the reasons investors can be optimistic about 2021 is the speed with which the first of the Covid-19 vaccines delivered Phase 3 data. On Monday 9 November the American pharmaceutical major Pfizer (NYSE: PFE) announced the results of an interim analysis showing that the BNT162b2 vaccine was more than 90% effective…

ByMarc KennisNovember 10, 2020